ClinicalTrials.gg
CompletedNCT06527677Updated Jul 29, 2025

Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects

A Phase 1 interventional study of ANT3310 and Meropenem in Renal Impairment, sponsored by Antabio. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Antabio · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Enrollment
58th of 113
41 · median 42
Started
2024
with 5 others
Phase 1
54 of 139
1 open now
Registered
130th of 139
by date

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 58th largest by enrollment of the 113 interventional ones that give a count, is one of 6 that started in 2024, is one of 54 in phase 1, and was the 130th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This is an open-label, non-randomized, single-center, single i.v. dose Phase 1 trial to evaluate the pharmacokinetics and safety of a combination of ANT3310 and meropenem in participants with different degrees of renal function impairment, including participants with End-Stage Renal Disease (ESRD), compared with matching control participants with normal renal function.

Read the detailed description

The participants will receive 1 single dose of the combination of ANT3310 and meropenem (2 times a single dose in participants with ESRD).

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Participant must be 18 to 80 years of age (both inclusive) at the time of signing the .
  • within the range of 18.0 to 36.0 kg/m2 (both inclusive) with a body weight ≥ 50 kg.
  • use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent in compliance with the requirements and restrictions listed in the ICF and in the protocol.
  • Ability to cooperate with the investigator and to comply with the requirements of the trial.
  • Sufficient venous access for i.v. infusion and PK samplings.
  • For participants with renal function impairment: Individualized \<90 mL/min at screening, estimated according to the individualized CKD-EPI equation and stable renal function.
  • For participants with ESRD requiring dialysis: Chronic intermittent hemodialysis for ≥3 months prior to dosing.
  • For participants with normal renal function: Individualized eGFR ≥90 mL/min at screening, estimated based on serum creatinine measured within 10 days prior to Day -1 according to the CKD-EPI equation.

Main Exclusion Criteria:

  • Febrile illness within 1 week before admission to the study center.
  • Known to meropenem and or ANT3310 or any of the of the infusion solution.
  • Known severe allergies, non-allergic drug reactions, or multiple drug allergies requiring intranasal or systemic during any time of the year or history of any anaphylactic reaction.
  • Medical disorder, condition, or history of such that would - in the opinion of the investigator - compromise the participant's ability to participate in this study.
  • History of epilepsy (or known seizure disorder), brain lesions or other significant neurological disorders.
  • Known history of hypersensitivity or urticaria, or severe allergic reaction to β-lactam antibiotics (e.g., penicillin, cephalosporin, carbapenem, or monobactam).
  • History of Gilbert syndrome.
  • History of any severe antibiotic-associated superinfections like Clostridium difficile colitis and/or frequent fungal vaginal infections.
  • Therapies (e.g., physiotherapy, acupuncture, etc.) within 1 week before study drug administration.
  • Positive results for , anti-, antibodies (anti-HIV 1+2).
  • For participants with impaired renal function: Acute renal failure or active renal infections, Clinically significant impaired hepatic function, Severe infection or any clinically significant illness within 4 weeks before dosing, Impairment of any other major organ system other than the kidney except underlying disease, Diagnosed during the past 5 years except completely resected basal cell cancer of the skin, Any kidney transplant during the last 10 years, any other organ transplant during the past 5 years.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    ANT3310 and Meropenem

    Participants with mild, moderate, or severe renal function impairment (Panel A, B, and D) and participants with normal renal function (Panel C and F) will receive 1 single dose of a combination of ANT3310 and meropenem. Participants with End Stage Renal Disease (Panel E) will receive 2 times a single dose of a combination of ANT3310 and meropenem: one single dose during dialysis-free interval ("off- dialysis") and one single dose on the day of dialysis ("on-dialysis"). The same dose will be given in both periods with a washout interval of at least 7 days between administrations.

    Drug: ANT3310 · Drug: Meropenem

Interventions

  • ANT3310 will be administered as a single intravenous infusion over 3 hours at a constant rate.

  • meropenem will be administered as a single intravenous infusion over 3 hours at a constant rate.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentrations (Cmax) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  2. Area under the curve from 0 to infinity (AUC0-inf) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  3. Time from dosing to maximum observed concentration (tmax) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  4. Apparent terminal elimination half-life (t1/2λz) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  5. Area under the curve from time 0 to time of last measurable concentration (AUC0-last) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  6. Area under the curve from time 0 to 48h (AUC0-48h) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  7. Percentage of AUC0-inf obtained by extrapolation (AUCext) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  8. Total body clearance (CL) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  9. Non-renal clearance (CLNonR) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma and urine.

    Time frame: From pre-dose to Day 3

  10. Apparent volume of distribution during the terminal phase after administration (Vz) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  11. Mean residence time (MRT) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in plasma.

    Time frame: From pre-dose to Day 3

  12. Amount of ANT3310 and Meropenem that is eliminated in urine from 0 to infinity (Ae0-inf) after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in urine.

    Time frame: From pre-dose to Day 3

  13. Renal clearance (CLR) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in urine.

    Time frame: From pre-dose to Day 3

  14. Fraction of dose recovered in urine (fe) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in urine.

    Time frame: From pre-dose to Day 3

  15. Amount of ANT3310 and Meropenem that is eliminated in urine from 0 to 48h (Ae0-48h) after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in urine.

    Time frame: From pre-dose to Day 3

  16. Fraction of dose recovered in urine from 0 to 48 hours (fe0-48h) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in urine.

    Time frame: From pre-dose to Day 3

  17. Renal clearance from 0 to 48 hours (CLR[0-48h]) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem

    Pharmacokinetic parameter of ANT3310 and Meropenem in urine.

    Time frame: From pre-dose to Day 3

  18. Dialysis clearance (CLD) of ANT3310 and Meropenem after a single i.v. infusion of the combination ANT3310-Meropenem in dialysed subjects

    Pharmacokinetic parameter of ANT3310 and Meropenem in dialysate and plasma.

    Time frame: during dialysis

Secondary outcomes

  1. Number and severity of treatment-emergent adverse event (TEAE) to evaluate the safety and tolerability of ANT3310 and meropenem after a single i.v. infusion of a combination of ANT3310 and meropenem.

    Percentage of participants experiencing ≥ one treatment-emergent adverse event (TEAE) by seriousness, intensity, and relatedness from baseline to end of study (EoS) or early withdrawal.

    Time frame: 0 hours to Day 9

  2. Number of participants who discontinue due to a TEAE.

    Percentage of participants who discontinue due to a TEAE.

    Time frame: 0 hours to Day 9

  3. Number of participants who meet the clinically significant abnormal criteria for safety laboratory tests at least once after start of dosing.

    Percentage of participants who meet the clinically significant abnormal criteria for safety laboratory tests at least once after start of dosing.

    Time frame: 0 hours to Day 9

  4. Number of participants meeting the clinically significant abnormal criteria for vital signs measurements at least once after start of dosing.

    Percentage of participants meeting the clinically significant abnormal criteria for vital signs (blood pressure, pulse rate, respiratory rate, and body temperature) measurements at least once after start of dosing.

    Time frame: 0 hours to Day 9

  5. Number of participants who meet the clinically significant abnormal criteria for ECG (Electrocardiogram) parameters.

    Percentage of participants who meet the clinically significant abnormal criteria for ECG parameters.

    Time frame: Day-1 to Day 9

  6. Number of infusion site reactions to assess local venous tolerability

    Time frame: From pre-dose on Day 1 to Day 3

07

Study locations

1 site
  • CRS Clinical Research Services Kiel GmbH
    Kiel, D-24105, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jul 2025, 11 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 30, 2024
StartActual
Jul 19, 2024
Primary completionActual
Jul 3, 2025
CompletionActual
Jul 10, 2025
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06527677
Lead sponsor
Antabio
Collaborators
Clinical Research Center Kiel GmbH
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Jul 19, 2024
Primary completion
Jul 3, 2025
Completion
Jul 10, 2025
Last update
Jul 29, 2025

Study contacts

Christian Zwingelstein, PharmD
study director · Antabio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pilabactam sodium

Start the discussion